Could Omega Fatty Acids Blunt an Immune Cell’s Cancer Defense? A Mouse Study Raises the Question

Omega fatty acids are widely taken as healthy supplements — and a mouse study suggests very high levels might, in some contexts, weaken a key cancer-fighting immune cell. It is an early finding, and not a reason to change your diet.

Researchers at Yale University School of Medicine found that omega polyunsaturated fatty acids — including omega-3 and omega-6 — can suppress the tumour-killing ability of natural killer cells. The work was published August 12, 2026 in Science Signaling.

The mechanism

The fats enter NK cells through a receptor called LRP5 and dial down the metabolic pathways — mTORC1 signalling and glycolysis — that NK cells need to attack tumours.

The metabolic angle is what makes this coherent rather than surprising. Killing a tumour cell is energetically demanding: an activated NK cell must proliferate, synthesise cytotoxic proteins and sustain the machinery to deliver them. Immune cells switch to glycolysis when activated precisely because it supports rapid biosynthesis, and mTORC1 is the master regulator coordinating that shift.

Suppressing those pathways does not make the cell recognise tumours less well. It makes the cell unable to act on what it recognises — which is a distinct and arguably harder failure to detect.

What the experiments showed

When researchers deleted the LRP5 receptor, NK cells became better at eliminating colon-cancer cells, and mice on a PUFA-free diet had slower tumour growth.

Two lines of evidence pointing the same way strengthens the case considerably. Removing the receptor addresses the mechanism directly; removing the dietary substrate addresses it from the other end. That both improve tumour control suggests the pathway is genuinely operating rather than being an artefact of one manipulation.

The therapeutic reading

That suggests LRP5 acts like an immune checkpoint restraining NK cells — a potential drug target.

The checkpoint framing is deliberate and apt. Checkpoint inhibitors transformed cancer treatment by removing brakes on T cells, and the same logic has been sought for NK cells with limited success. If LRP5 is a genuine brake, blocking it would be a checkpoint strategy for a cell population current immunotherapy largely does not reach.

That is the substantive finding here — not a dietary warning but the identification of a druggable restraint on an immune cell type that has been difficult to mobilise.

Why this should not change what anyone eats

This is early, mouse-based research, and it is not evidence that fish-oil supplements cause cancer or that anyone should stop taking them. Omega fatty acids have well-documented benefits, particularly cardiovascular.

Several things separate this from a dietary implication. The mice were fed a PUFA-free diet — a complete absence, not a reduction, and a condition no human diet approximates. Omega-3 and omega-6 fatty acids are also essential nutrients: the body cannot synthesise them, and genuine deficiency causes serious problems.

The study also concerns tumour immunity specifically, in mice with implanted cancers. Extrapolating from that to whether a healthy person’s supplement intake affects their cancer risk requires several unjustified steps.

The measured framing

First author Yi Luan noted only that “greater public awareness of their potential unintended effects is warranted” given how heavily supplements are promoted.

That is a defensible and narrow claim. Supplements are marketed as unambiguously beneficial and are consumed at doses well above dietary intake, frequently without medical advice — and the assumption that more of a beneficial nutrient is better is one that biology does not generally support.

The omega-3 versus omega-6 question the study leaves open

One notable feature is that the effect covered both omega-3 and omega-6 fatty acids.

Nutritional discussion usually treats these as opposites — omega-3 anti-inflammatory and beneficial, omega-6 pro-inflammatory and consumed in excess. A mechanism operating through a shared receptor and affecting both equally does not fit that framing, and suggests the relevant variable may be total polyunsaturated fat load rather than the ratio that dominates dietary advice.

Whether that holds in humans is untested, and it is the sort of finding that would complicate a widely repeated nutritional message if it did.

Why immunometabolism keeps producing findings like this

The study belongs to a field that has grown rapidly over the past decade, and the underlying insight explains why such results keep appearing.

Immune cells change their metabolism dramatically depending on what they are doing. A resting cell runs on efficient oxidative metabolism; an activated one switches to glycolysis, which produces less energy per glucose molecule but supplies the building blocks for rapid proliferation and protein synthesis.

That means metabolic conditions are not background to immune function — they are part of it. Nutrient availability, oxygen levels, competing cells consuming the same fuel, and the accumulated waste products of tumour metabolism all shape what an immune cell can do.

Tumours exploit this. They consume glucose voraciously, acidify their surroundings and generate metabolites that impair immune cell function — a form of suppression that operates through chemistry rather than through the checkpoint signalling that immunotherapy targets. Findings about lipids constraining NK cell metabolism sit squarely in that frame, and the therapeutic implication is that removing metabolic constraints may prove as important as removing signalling brakes.

The real promise here is scientific: targeting LRP5 might one day strengthen the immune system against cancer. This describes early animal research and is not dietary or medical advice. Do not change your supplement use based on it.